Sonoma Pharmaceuticals, Inc. (SNOA)Healthcare | Drug Manufacturers - Specialty & Generic | Boulder, United States | NasdaqCM
2.30 USD
+0.09
(4.072%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 2.10 -0.20 (-0.200%) ⇩ (April 17, 2026, 7:49 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:26 p.m. EDT
Catastrophic long-term fundamentals (losses, negative P/E, high debt-to-equity) contradict short-term speculative pop driven exclusively by retail hype from new retail pipeline launches; model forecasts a >3% decline over the next 45 days, warning of a likely momentum sell-off. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.195453 |
| MSTL | 0.198295 |
| AutoETS | 0.209511 |
| AutoARIMA | 0.269468 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 14.10 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.446 |
| Excess Kurtosis | -0.92 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 19.085 |
| Revenue per Share | 10.718 |
| Market Cap | 3,980,409 |
| Forward P/E | -4.11 |
| Beta | 1.76 |
| Profit Margins | -19.02% |
| Website | https://sonomapharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.036036015 |
| Address1 | 5,445 Conestoga Court |
| Address2 | Suite 150 |
| All Time High | 72,324.0 |
| All Time Low | 1.75 |
| Ask | 2.88 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 24,860 |
| Average Daily Volume3 Month | 23,356 |
| Average Volume | 23,356 |
| Average Volume10Days | 24,860 |
| Beta | 1.764 |
| Bid | 1.65 |
| Bid Size | 2 |
| Book Value | 1.983 |
| City | Boulder |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.3 |
| Current Ratio | 2.88 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.335 |
| Day Low | 2.21 |
| Debt To Equity | 19.085 |
| Display Name | Sonoma Pharmaceuticals |
| Dividend Date | 1,560,988,800 |
| Earnings Timestamp End | 1,754,942,400 |
| Earnings Timestamp Start | 1,754,510,400 |
| Ebitda | -2,629,000 |
| Ebitda Margins | -0.14835 |
| Enterprise To Ebitda | -0.789 |
| Enterprise To Revenue | 0.117 |
| Enterprise Value | 2,074,409 |
| Eps Current Year | -1.61 |
| Eps Forward | -0.56 |
| Eps Trailing Twelve Months | -1.95 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.542 |
| Fifty Day Average Change | -0.2420001 |
| Fifty Day Average Change Percent | -0.095200665 |
| Fifty Two Week Change Percent | 3.6036015 |
| Fifty Two Week High | 6.92 |
| Fifty Two Week High Change | -4.62 |
| Fifty Two Week High Change Percent | -0.66763 |
| Fifty Two Week Low | 2.0 |
| Fifty Two Week Low Change | 0.29999995 |
| Fifty Two Week Low Change Percent | 0.14999998 |
| Fifty Two Week Range | 2.0 - 6.92 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,169,735,400,000 |
| Float Shares | 1,710,434 |
| Forward Eps | -0.56 |
| Forward P E | -4.107143 |
| Free Cashflow | -3,573,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 8 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.38155997 |
| Gross Profits | 6,762,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01166 |
| Held Percent Institutions | 0.06293 |
| Implied Shares Outstanding | 1,730,613 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Ir Website | http://ir.oculusis.com/ |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,743,379,200 |
| Last Split Date | 1,724,976,000 |
| Last Split Factor | 1:20 |
| Long Business Summary | Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado. |
| Long Name | Sonoma Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 3,980,409 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_8652169 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -3,370,000 |
| Next Fiscal Year End | 1,774,915,200 |
| Non Diluted Market Cap | 3,980,409 |
| Number Of Analyst Opinions | 1 |
| Open | 2.21 |
| Operating Cashflow | -3,509,000 |
| Operating Margins | -0.1559 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.08 |
| Phone | 800 759 9305 |
| Post Market Change | -0.20000005 |
| Post Market Change Percent | -8.695654 |
| Post Market Price | 2.1 |
| Post Market Time | 1,776,469,777 |
| Previous Close | 2.21 |
| Price Eps Current Year | -1.4285713 |
| Price Hint | 4 |
| Price To Book | 1.1598587 |
| Price To Sales Trailing12 Months | 0.2246027 |
| Profit Margins | -0.19016 |
| Quick Ratio | 1.207 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0899999 |
| Regular Market Change Percent | 4.07239 |
| Regular Market Day High | 2.335 |
| Regular Market Day Low | 2.21 |
| Regular Market Day Range | 2.21 - 2.335 |
| Regular Market Open | 2.21 |
| Regular Market Previous Close | 2.21 |
| Regular Market Price | 2.3 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 7,439 |
| Return On Assets | -0.12669 |
| Return On Equity | -0.81184995 |
| Revenue Growth | 0.22 |
| Revenue Per Share | 10.718 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 1,730,613 |
| Shares Percent Shares Out | 0.0225 |
| Shares Short | 38,967 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 12,975 |
| Short Name | Sonoma Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.0294 |
| Short Ratio | 1.23 |
| Source Interval | 15 |
| State | CO |
| Symbol | SNOA |
| Target High Price | 12.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 12.0 |
| Target Median Price | 12.0 |
| Total Cash | 2,561,000 |
| Total Cash Per Share | 1.48 |
| Total Debt | 655,000 |
| Total Revenue | 17,722,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.95 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.45475 |
| Two Hundred Day Average Change | -1.1547501 |
| Two Hundred Day Average Change Percent | -0.33424997 |
| Type Disp | Equity |
| Volume | 7,439 |
| Website | https://sonomapharma.com |
| Zip | 80,301 |